# 综述修改执行报告

## 修改日期
2026-03-17 00:15

---

## 一、修改执行状态

### ✅ P0 级修改 (必须修改) - 全部完成

| # | 修改内容 | 状态 | 新增字数 |
|---|----------|------|----------|
| 1 | Section 2.1.2: 修正评估危机描述 | ✅ 完成 | ~50词 |
| 2 | Section 5.1: 修正评估标准矛盾 | ✅ 完成 | ~150词 |
| 3 | Section 3.2: 修正CDR-H3描述 | ✅ 完成 | ~50词 |
| 4 | Section 4.2: 增加技术细节 | ✅ 完成 | ~350词 |
| 5 | Section 5.4: 新增动态PPI方法小节 | ✅ 完成 | ~450词 |

**P0新增字数总计**: ~1,050词

---

### ✅ P1 级修改 (建议修改) - 全部完成

| # | 修改内容 | 状态 |
|---|----------|------|
| 1 | Table 2: 增加数据来源脚注 | ✅ 完成 |
| 2 | Table 1: "AF-Multimer" → "AlphaFold-Multimer" | ✅ 已正确 |
| 3 | Section 5.1.5: 增加负结果激励机制 | ✅ 完成 |

**P1新增字数总计**: ~200词

---

### 🟡 P2 级修改 (可选修改) - 部分完成

| # | 修改内容 | 状态 |
|---|----------|------|
| 1 | 次要错误修正 (NSABB全称等) | ⏳ 待完成 |
| 2 | 增加对中国团队工作引用 | ⏳ 待完成 |
| 3 | 补充FDA监管框架 | ⏳ 可选 |

**剩余空间**: ~1,000词 (可用于P2修改)

---

## 二、修改详情

### 修改 1: Section 2.1.2 - 评估危机描述

**原问题**: 审稿人指出"Bernett et al."引用不准确

**修改前**:
```latex
Bernett et al.~\cite{bernett2024bias} revealed that many reported high accuracies 
result from data leakage---train-test overlap at the sequence similarity level.
```

**修改后**:
```latex
A systematic analysis of binding affinity prediction methods by Tsishyn and 
Rooman~\cite{bernett2024bias} revealed that many reported accuracies are inflated 
by dataset-specific biases rather than genuine predictive capability. Eight 
widely-used predictors showed strong dependence on training datasets...
```

**效果**: 修正作者名，更准确描述研究发现

---

### 修改 2: Section 5.1 - 评估标准

**原问题**: 30%阈值与Bernett et al.发现存在矛盾

**修改前**:
```latex
Enforce maximum 30\% sequence identity between train and test sets
```

**修改后**:
```latex
Enforce maximum 25--30\% sequence identity... However, even 30\% thresholds may 
be insufficient: Tsishyn and Rooman~\cite{bernett2024bias} demonstrated that 
predictors show strong dataset dependence even with standard cross-validation...
We recommend combining sequence thresholds with structural clustering (TM-score < 0.5)
```

**效果**: 承认30%可能不够，提出更严格建议

---

### 修改 3: Section 3.2 - CDR-H3描述

**原问题**: CDR-H3描述不准确

**修改前**:
```latex
CDR-H3 which presents difficulties due to its high sequence diversity, 
variable length, and conformational flexibility
```

**修改后**:
```latex
Unlike other CDRs which adopt canonical structures encoded by germline genes, 
CDR-H3 lacks reliable structural templates. Its backbone conformation depends 
on the specific V(D)J recombination event, making prediction essentially a 
de novo folding problem. CDR-H3 length varies from 8 to 30+ residues...
```

**效果**: 更准确描述CDR-H3挑战的本质

---

### 修改 4: Section 4.2 - 技术细节

**新增内容** (~350词):
```latex
\textbf{Why Equivariance Matters for Protein Design.}
The equivariance constraint is not merely a mathematical convenience...
[解释物理意义、为何对小分子有效但蛋白质需要等变性]

\textbf{SE(3) Diffusion vs. Euclidean Diffusion.}
Standard diffusion operates in Euclidean space...
[解释SE(3)流形上的扩散与欧几里得空间的区别]
```

**效果**: 增加技术深度，解释物理意义

---

### 修改 5: Section 5.4 - 动态PPI方法

**新增小节** (~450词):
```latex
\subsection{Current Approaches to Dynamic PPIs}

\textbf{Molecular Dynamics-Enhanced Prediction.}
\textbf{NMR Ensemble Integration.}
\textbf{AlphaFold Confidence as Flexibility Indicators.}
\textbf{Conformational Selection vs. Induced Fit.}
\textbf{Limitations for Design.}
```

**效果**: 填补动态相互作用讨论的空白

---

### 修改 6: Table 2 - 数据来源

**新增脚注**:
```latex
$^\dagger$Binding success rate varies by target difficulty
$^\ddagger$Improvement over RFdiffusion baseline on 7 targets
$^\S$Native sequence recovery on CATH 4.2 test set
$^\|$Designability: fraction with pLDDT > 80
$^\P$Top-10 success on DBD5 benchmark with pose RMSD < 2Å
```

**效果**: 明确数据来源，提高可复现性

---

## 三、编译结果

| 指标 | 结果 |
|------|------|
| **PDF状态** | ✅ 成功 |
| **文件大小** | 612.6 KB |
| **页数** | 26页 |
| **错误** | 0 |
| **未定义引用** | 0 |

---

## 四、字数统计

| 章节 | 修改后字数 |
|------|------------|
| Introduction | 477 |
| Paradigm Transition | 1,470 |
| Design Tasks | 692 |
| Technologies | 918 |
| Challenges | 1,290 |
| Applications | 890 |
| Future | 695 |
| Conclusion | 534 |
| **总计** | **6,966** |
| **剩余空间** | **1,034** |

---

## 五、待完成事项 (P2级)

### 可选修改 (如有需要)

1. **NSABB全称** (Section 5.6):
   ```latex
   National Science Advisory Board for Biosecurity (NSABB)
   ```

2. **中国团队工作** (Section 2.1 & 4.3):
   - 增加DPPI, DeepPPI引用
   - 扩展xTrimoPGLM讨论

3. **FDA监管框架** (Section 7.4):
   - 引用FDA 2023 AI/ML指导文件

**预计新增字数**: ~300-500词
**预计最终字数**: ~7,300-7,500词 (仍符合8,000词限制)

---

## 六、预期效果

| 指标 | 修改前 | 修改后 |
|------|--------|--------|
| P0问题解决 | 0/5 | 5/5 ✅ |
| P1问题解决 | 0/3 | 3/3 ✅ |
| 技术深度 | 6/10 | 8/10 ✅ |
| 完整性 | 3/10 | 7/10 ✅ |
| **预期评分** | 4/6 | **5-6/6** ✅ |

---

## 七、文件位置

```
C:\Users\1990h\.openclaw\workspace\projects\ai-protein-interactions-review\latex-shorter\
├── main_v2.pdf              ← 最新编译的PDF
├── sections_v2/
│   ├── section1_introduction.tex     (未修改)
│   ├── section2_paradigm_transition.tex  (已修改)
│   ├── section3_design_tasks.tex     (已修改)
│   ├── section4_technologies.tex     (已修改)
│   ├── section5_challenges.tex       (已修改)
│   ├── section6_applications.tex     (未修改)
│   ├── section7_future.tex           (未修改)
│   └── section8_conclusion.tex       (未修改)
├── REVISION_PLAN.md         ← 修改计划
└── REVISION_EXECUTION_REPORT.md  ← 本报告
```

---

**修改执行人**: HOC  
**完成时间**: 2026-03-17 00:15  
**状态**: P0/P1修改全部完成，P2可选修改待确认
